Literature DB >> 8627706

Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.

L V Gubareva1, R Bethell, G J Hart, K G Murti, C R Penn, R G Webster.   

Abstract

The development of viral resistance to the neuraminidase (NA) inhibitor, 4-guanidino-Neu5Ac2en, of influenza viruses was studied by serial passage of A/Turkey/Minnesota/833/80 (H4N2) in Madin-Darby canine kidney cells in the presence of increasing concentrations of inhibitor. Resistant mutants selected after eight passages, had a 10,000-fold reduction in sensitivity to the inhibitor in plaque assays, but their affinity (1/Kd) to the inhibitor was similar to that of the parental virus. Electron microscopic analysis revealed aggregation of the mutant virus at the cell surface in the presence of the inhibitor. Sequence analysis established that a substitution had occurred in the NA (Arg-249 to Lys) and in the HA2 subunit of the hemagglutinin (Gly-75 to Glu), in the vicinity of the proposed second sialic acid binding site. The change of residue 249 appears to be a chance mutation, for we were unable to reisolate this mutant, whereas subsequent experiments indicate changes in the hemagglutinin. After 13 passages of the parental virus, mutants that were resistant to the high concentrations of inhibitor tested were obtained. These viruses retained their drug-resistant phenotype even after five passages without the inhibitor. Electron microscopic analysis revealed no aggregation of virus on the surface of infected cells in the presence of the inhibitor. Sequence analysis of the NA gene from these drug-resistant mutants revealed an additional substitution of Glu to Ala at the conserved amino acid residue 119. This substitution is responsible for reducing the affinity of the inhibitor to the NA. Our findings suggest that the emergence of mutants resistant to 4-guanidine-Neu5Ac2en is a multistep process requiring prolonged exposure to the inhibitor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627706      PMCID: PMC190009     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2).

Authors:  E E Mast; M W Harmon; S Gravenstein; S P Wu; N H Arden; R Circo; G Tyszka; A P Kendal; J P Davis
Journal:  Am J Epidemiol       Date:  1991-11-01       Impact factor: 4.897

2.  Crystallographic detection of a second ligand binding site in influenza virus hemagglutinin.

Authors:  N K Sauter; G D Glick; R L Crowther; S J Park; M B Eisen; J J Skehel; J R Knowles; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Rational design of potent sialidase-based inhibitors of influenza virus replication.

Authors:  M von Itzstein; W Y Wu; G B Kok; M S Pegg; J C Dyason; B Jin; T Van Phan; M L Smythe; H F White; S W Oliver
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

4.  Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid.

Authors:  G P Thomas; M Forsyth; C R Penn; J W McCauley
Journal:  Antiviral Res       Date:  1994-08       Impact factor: 5.970

5.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase.

Authors:  P M Colman; J N Varghese; W G Laver
Journal:  Nature       Date:  1983 May 5-11       Impact factor: 49.962

6.  Biologic potential of amantadine-resistant influenza A virus in an avian model.

Authors:  W J Bean; S C Threlkeld; R G Webster
Journal:  J Infect Dis       Date:  1989-06       Impact factor: 5.226

7.  4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.

Authors:  J M Woods; R C Bethell; J A Coates; N Healy; S A Hiscox; B A Pearson; D M Ryan; J Ticehurst; J Tilling; S M Walcott
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position.

Authors:  C T Holzer; M von Itzstein; B Jin; M S Pegg; W P Stewart; W Y Wu
Journal:  Glycoconj J       Date:  1993-02       Impact factor: 2.916

9.  Evidence for host-cell selection of influenza virus antigenic variants.

Authors:  G C Schild; J S Oxford; J C de Jong; R G Webster
Journal:  Nature       Date:  1983 Jun 23-29       Impact factor: 49.962

10.  Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.

Authors:  F G Hayden; R B Belshe; R D Clover; A J Hay; M G Oakes; W Soo
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

View more
  59 in total

Review 1.  Oseltamivir: a review of its use in influenza.

Authors:  K McClellan; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.

Authors:  Hui-Ling Yen; Erich Hoffmann; Garry Taylor; Christoph Scholtissek; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

Review 4.  Role of combination antiviral therapy in pandemic influenza and stockpiling implications.

Authors:  Sotirios Tsiodras; John D Mooney; Angelos Hatzakis
Journal:  BMJ       Date:  2007-02-10

5.  HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

Authors:  Michael D Altman; Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Sripriya Chellappan; Visvaldas Kairys; Miguel X Fernandes; Michael K Gilson; Celia A Schiffer; Tariq M Rana; Bruce Tidor
Journal:  J Am Chem Soc       Date:  2008-04-16       Impact factor: 15.419

6.  Attenuation of influenza A virus mRNA levels by promoter mutations.

Authors:  E Fodor; P Palese; G G Brownlee; A García-Sastre
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

7.  Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.

Authors:  S Bantia; A A Ghate; S L Ananth; Y S Babu; G M Air; G M Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

9.  Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.

Authors:  Jenna E Achenbach; Richard A Bowen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.

Authors:  Natalia A Ilyushina; Jon P Seiler; Jerold E Rehg; Robert G Webster; Elena A Govorkova
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.